Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer

Annals of Surgery

Volumn 255, Issue 1, 2012, Pages 140-146

  Demeure, Michael J ^a,b   Stephan, Elizabeth ^b   Sinari, Shripad ^b   Mount, David ^c   Gately, Steven ^b   Gonzales, Paul ^b   Hostetter, Galen ^b   Komorowski, Richard ^d   Kiefer, Jeff ^b   Grant, Clive S ^e   Han, Haiyong ^b   Von Hoff, Daniel D ^a,b   Bussey, Kimberly J ^b  

^a Virginia G Piper Cancer Center   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; NANOPARTICLE; NUCLEAR MATRIX PROTEIN; PACLITAXEL; SECRETED PROTEIN ACIDIC RICH IN CYSTEINE; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; HUMANS; MICE; MITOTANE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PACLITAXEL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84155162799     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182402d21     Document Type: Article

References (21)

1. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992; 112:972-979; discussion 979-980.
2. Demeure MJ, Somberg LB. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. Surg Oncol Clin N Am. 1998;7:791-805. (Pubitemid 28436540)
3. Bergenstal DM, Lipsett M, Moy RN, et al. Regression of adrenal cancer and suppression of adrenal function in man by o, p'-DDD. Trans Am Phys. 1959;72:341-350.
4. Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery. 1991;110:1006-1013.
5. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6:386-394. (Pubitemid 40561415)
6. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998;83:2194-2200. (Pubitemid 28525402)
7. Flynn SD, Murren JR, Kirby WM, et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992;112:981-986. (Pubitemid 23008222)
8. Abraham J, Bakke S, Rutt A, et al. Aphase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposidewith dailymitotane as a P-glycoprotein antagonist. Cancer. 2002;94:2333-2343. (Pubitemid 34457113)
9. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247-1259. (Pubitemid 20239995)
10. Fallo F, Pilon C, Barzon L, et al. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy. 1998;44:129-134. (Pubitemid 28105426)
11. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136-4143. (Pubitemid 40791578)
12. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albuminbound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317-1324. (Pubitemid 43342524)
13. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803. (Pubitemid 46657376)
14. Clark CJ, Sage EH. A prototypic matricellular protein in the tumor microenvironment-where there's SPARC, there's fire. J Cell Biochem. 2008;104:721-732. (Pubitemid 351830824)
15. Reed MJ, Sage EH. SPARC and the extracellular matrix: implications for cancer and wound repair. Curr Top Microbiol Immunol. 1996;213:81-94. (Pubitemid 26165087)
16. Thomas R, True LD, Bassuk JA, et al. Differential expression of osteonectin/ SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6:1140-1149. (Pubitemid 30159378)
17. Wang CS, Lin KH, Chen SL, et al. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 2004;91:1924-1930.
18. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23:7785-7593.
19. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol. 2006;17:735-749.
20. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001;298:1236-1242. (Pubitemid 32761945)
21. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657-666. (Pubitemid 41482999)